Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 5:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 83,794 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: therapy Clear all
Completed Phase 1 Interventional

Safety Study to Examine the Systemic Exposure of Granexin® Gel After Topical Application to Venous Leg Ulcers

NCT02652572
View directory record Official record
Conditions
Venous Leg Ulcer
Interventions
Granexin
Drug
Lead sponsor
Xequel Bio, Inc.
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
3
States / cities
Augusta, Georgia • Spartanburg, South Carolina • Salem, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Oct 19, 2026, 5:32 PM EDT
Completed Phase 3 Interventional Results available

A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma

NCT03345095
View directory record Official record
Conditions
Newly Diagnosed Glioblastoma
Interventions
Marizomib, Temozolomide, radiotherapy
Drug · Radiation
Lead sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Network
Eligibility
18 Years and older
Enrollment
749 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
9
States / cities
Scottsdale, Arizona • Orange, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Oct 19, 2026, 5:32 PM EDT
Completed Phase 4 Interventional Results available

Black Education and Treatment of Hypertension (BEAT HTN)

NCT00661895
View directory record Official record
Conditions
Hypertension
Interventions
Hydrochlorothiazide, Lisinopril, Lisinopril and Hydrochlorothiazide, Nifedipine XL, Metoprolol tartrate, Atenolol, Valsartan, Doxazosin, Clonidine, Hydralazine, Metoprolol succinate, Amlodipine
Drug
Lead sponsor
Creighton University
Other
Eligibility
25 Years to 80 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 4, 2012 · Synced Oct 19, 2026, 5:32 PM EDT
Completed Phase 2 Interventional Results available

VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL) in Individuals Seronegative for Human Immunodeficiency Virus (HIV)-1/2

NCT03499795
View directory record Official record
Conditions
Anal Neoplasm
Interventions
VGX-3100, CELLECTRA™ 5PSP
Biological · Device
Lead sponsor
Inovio Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 14, 2023 · Synced Oct 19, 2026, 5:32 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas

NCT06090539
View directory record Official record
Conditions
Relapsed/Refractory Non-Hodgkin Lymphoma
Interventions
BMS-986458, Rituximab, Glofitamab/Obinutuzumab, Mosunetuzumab, Epcoritamab, Golcadomide
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
11
States / cities
Phoenix, Arizona • Duarte, California • Jacksonville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 19, 2026, 5:32 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed Children

NCT01854775
View directory record Official record
Conditions
Acquired Immune Deficiency Syndrome (AIDS), HIV Infections
Interventions
E/C/F/TAF, E/C/F/TAF (Low Dose)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
2 Years to 17 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2025
U.S. locations
5
States / cities
Long Beach, California • Washington D.C., District of Columbia • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2026 · Synced Oct 19, 2026, 5:32 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Hypovitaminosis D in Neurocritical Patients

NCT02881957
View directory record Official record
Conditions
Craniocerebral Trauma, Intracranial Aneurysm, Brain Neoplasms, Spinal Cord Injuries, Seizures, Meningitis, Stroke, Intracranial Hemorrhages, Critical Illness, Vitamin d Deficiency
Interventions
Cholecalciferol, Placebo
Drug · Other
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 15, 2022 · Synced Oct 19, 2026, 5:32 PM EDT
Recruiting Phase 1 Interventional

IDOV-Immune for Advanced Solid Tumors

NCT06910657
View directory record Official record
Conditions
Colorectal Cancer, Pancreatic Cancer, Melanoma, Ovarian Cancer, Gastric Cancer, Esophageal Cancer, Hepatocellular Carcinoma, Renal Cell Carcinoma, Breast Cancer, Sarcoma, Bladder Cancer, Lung Cancer, Prostate Cancer, Cervical Cancers, Head and Neck Cancers, Adrenal Gland Tumors
Interventions
IDOV-Immune (oncolytic vaccinia virus)
Biological
Lead sponsor
ViroMissile, Inc.
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
St Louis, Missouri • Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 19, 2026, 5:32 PM EDT
Recruiting Phase 2 Interventional

Prescription Opioids, Brain Structure, and Cognition in Older Adults With Chronic Pain

NCT06837857
View directory record Official record
Conditions
Pain, Chronic
Interventions
Opioid, Opioid Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
65 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 19, 2026, 5:32 PM EDT
Withdrawn Phase 2 Interventional

Fecal Microbiota Transplantation For The Treatment Of Gastro-Intestinal Acute GVHD

NCT04059757
View directory record Official record
Conditions
Gastro-Intestinal Acute Graft Versus Host Disease (GI-aGVHD)
Interventions
Fecal Microbiota Transplantation (FMT)
Biological
Lead sponsor
Leland Metheny
Other
Eligibility
19 Years to 74 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 7, 2022 · Synced Oct 19, 2026, 5:32 PM EDT
Completed Phase 4 Interventional Results available

A Study Comparing Duloxetine to Other Antidepressants in the Treatment of Severe Depression

NCT00666757
View directory record Official record
Conditions
Depression
Interventions
duloxetine, fluoxetine, citalopram, paroxetine, sertraline
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
61
States / cities
Carson, California • Irvine, California • San Diego, California + 58 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2010 · Synced Oct 19, 2026, 5:32 PM EDT
Not listed Phase 3 Interventional

Randomized Study of Combination Chemotherapy With or Without Focused Microwave Thermotherapy Before Surgery in Treating Women With Large Breast Cancer Tumors

NCT01204801
View directory record Official record
Conditions
Breast Cancer
Interventions
Focused Microwave Thermotherapy, Chemotherapy (control)
Device · Drug
Lead sponsor
Medifocus, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Sep 24, 2015 · Synced Oct 19, 2026, 5:32 PM EDT
Completed Phase 2 Interventional Results available

A Research Study of Bone Marrow Transplantation From Unrelated or Partially Matched Related Donors

NCT01349101
View directory record Official record
Conditions
Hematological Malignancies
Interventions
Total Body Irradiation, Cyclophosphamide, Tacrolimus, Mycophenolate mofetil, Fludarabine, Busulfan, Hematopoietic stem cell transplantation
Radiation · Drug · Genetic
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 19, 2026, 5:32 PM EDT
Not listed Not applicable Interventional

Safety and Effectiveness of the CustomFlex Artificial Iris Prosthesis for the Treatment of Iris Defects

NCT01860612
View directory record Official record
Conditions
Full Aniridia, Partial Aniridia
Interventions
Artificial Iris (CustomFlex)
Device
Lead sponsor
Clinical Research Consultants, Inc.
Industry
Eligibility
3 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2025
U.S. locations
13
States / cities
Los Angeles, California • Atlanta, Georgia • Indianapolis, Indiana + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2022 · Synced Oct 19, 2026, 5:32 PM EDT
Completed Phase 2 Interventional

PH 2 ADI-PEG 20 Acute Myeloid Leukemia

NCT01910012
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
ADI-PEG 20
Drug
Lead sponsor
Polaris Group
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 1, 2020 · Synced Oct 19, 2026, 5:32 PM EDT
Terminated Phase 2 Interventional Results available

Docetaxel Followed by Surgery in Treating Women With Stage II or Stage III Breast Cancer

NCT00343512
View directory record Official record
Conditions
Breast Cancer
Interventions
docetaxel, protein expression analysis, laboratory biomarker analysis, biopsy, conventional surgery, neoadjuvant therapy
Drug · Genetic · Other + 1 more
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
2
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 27, 2012 · Synced Oct 19, 2026, 5:32 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Clinical Study on Prodovite® VMP35 Supplement on Athletic Performance

NCT04121481
View directory record Official record
Conditions
Athletic Performance
Interventions
Clinical Investigation on Enhanced Sports Nutrition and Performance Activities by Prodovite VMP35 Supplement, Broad Spectrum Safety
Dietary Supplement
Lead sponsor
Victory Nutrition International, Inc.
Industry
Eligibility
18 Years to 74 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Cornelius, North Carolina
Source: ClinicalTrials.gov public record
Updated May 7, 2021 · Synced Oct 19, 2026, 5:32 PM EDT
Completed Not applicable Interventional Results available

TrueRelief Efficacy for Post-cesarean Pain (ELECTRON)

NCT05250830
View directory record Official record
Conditions
Post-cesarean Pain
Interventions
TrueRelief device, Sham TrueRelief device
Device
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 6, 2024 · Synced Oct 19, 2026, 5:32 PM EDT
Recruiting Early Phase 1 Interventional

Active Surveillance and Chemotherapy Before Surgery in Treating Participants With Stage II-III Rectal Cancer

NCT03594630
View directory record Official record
Conditions
Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v8, Stage IIA Rectal Cancer AJCC v8, Stage IIB Rectal Cancer AJCC v8, Stage IIC Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Stage IIIA Rectal Cancer AJCC v8, Stage IIIB Rectal Cancer AJCC v8, Stage IIIC Rectal Cancer AJCC v8
Interventions
Chemotherapy, Patient Observation, Questionnaire Administration, Resection of Rectum
Drug · Other · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 19, 2026, 5:32 PM EDT
Completed Phase 3 Interventional

Radiation Therapy Plus Porfiromycin in Treating Patients With Stage III or Stage IV Head and Neck Cancer

NCT00003328
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
porfiromycin, radiation therapy
Drug · Radiation
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Peoria, Illinois • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated May 21, 2010 · Synced Oct 19, 2026, 5:32 PM EDT
Completed No phase listed Observational

Psychosocial Support for Cancer Patients

NCT00133965
View directory record Official record
Conditions
Cancer
Interventions
Dignity Psychotherapy, Supportive Psychotherapy, Standard Palliative Care
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
281 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 20, 2011 · Synced Oct 19, 2026, 5:32 PM EDT
Completed Phase 3 Interventional

Efficacy Study of Rezular (Arverapamil) in the Treatment of Irritable Bowel Syndrome With Diarrhea (IBS-D)

NCT00552565
View directory record Official record
Conditions
Irritable Bowel Syndrome With Diarrhea
Interventions
Rezular 15mg, Placebo, Rezular
Drug
Lead sponsor
AGI Therapeutics, Inc.
Other
Eligibility
18 Years to 70 Years
Enrollment
711 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 11, 2009 · Synced Oct 19, 2026, 5:32 PM EDT
Completed Phase 4 Interventional

Optimizing Prograf® Therapy in Renal Transplant Patients

NCT00297765
View directory record Official record
Conditions
Renal Transplantation
Interventions
Tacrolimus, Prograf®
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
42
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 34 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2008 · Synced Oct 19, 2026, 5:32 PM EDT
Terminated Not applicable Interventional Results available

Early Versus Late Use of Ibuprofen for Patent Ductus Arteriosus (PDA) Closure

NCT00833365
View directory record Official record
Conditions
Patent Ductus Arteriosus, Prematurity
Interventions
Ibuprofen
Drug
Lead sponsor
University of Utah
Other
Eligibility
Up to 96 Hours
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 4, 2016 · Synced Oct 19, 2026, 5:32 PM EDT